Get answers to your Myelodysplastic Syndromes questions.
The Program for Hematologic Malignancies is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) has been at the forefront of developing and testing new therapies for hematologic malignancies.
As one of the largest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma. Our center is a member of the Myeloproliferative Disorders Research Consortium, an NIH-funded international clinical trials group focusing on myeloproliferative disorders.
Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:
Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.